Company intelligence / Profile preview

Axoltis Pharma

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Axoltis Pharma has completed a successful phase Ia study with its lead candidate NX210c, demonstrating good safety and significant pharmacodynamic effects. The phase Ib trial showed promising results regarding neuroprotection, neurotransmission, and maintenance of blood-brain barrier integrity. The company plans further clinical development including a phase II trial in ALS and an expanded phase Ib trial in Parkinson’s Disease patients.

Therapeutic areas: Neurology
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

nx210c

Partnerships

InSilicoTrials

Beyond the preview

Go deeper on Axoltis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axoltis Pharma.